Tolmetin sodium is a non-steroidal anti-inflammatory drug (NSAID). Tolmetin sodium is an orally active and potent inhibitor of COX with IC 50s of 0.35 μM for human COX-1 and 0.82 μM for human COX-2, respectively [1] [2].

Tolmetin sodium (0.25 mM) does not attenuate lipid peroxidation in rat brain homogenate. Tolmetin (0.25, 0.5, 0.75, 1 mM) shows radical scavenging properties but without superoxide anion generation in rat brain homogenat [3]. Tolmetin sodium (0.001-100 μM) shows anticancer activity againts HT-29 colon cancer cell line in a dose-dependent manner [4]. Tolmetin sodium (0-100 μM) shows no effect on osteoblast growth [5].

Tolmetin sodium (30,100 mg/kg; gavage; single dose or twice daily for 3 and 14 days) shows maximal ulcerogenic effect 4 h after the single dose, while potently decreases after 3 and 14 days of repeated administration in male Wistar rats weighing 180-200 g. Tolmetin causes gastric lesions in 100 mg/kg [2]. Tolmetin sodium (5 mg/kg twice a day for 5 days) pre-treatment considerably attenuates quinolinic acid (QA)-induced neurotoxicity [3].